Navid Shomali

机构：Tabriz University of Medical Sciences · ORCID：0000-0003-4679-9658

发表论文 90 篇 · 总被引 3882 次 · h-index 33

代表论文

• Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons (2022 · Cell Communication and Signaling · 被引 521)
• Cancer combination therapies by angiogenesis inhibitors; a comprehensive review (2022 · Cell Communication and Signaling · 被引 200)
• Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients (2021 · Stem Cell Research & Therapy · 被引 134)
• Emerging role of mesenchymal stromal cells (MSCs)-derived exosome in neurodegeneration-associated conditions: a groundbreaking cell-free approach (2022 · Stem Cell Research & Therapy · 被引 98)
• Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction (2022 · Cancer Cell International · 被引 96)
• Therapeutic utility of mesenchymal stromal cell (MSC)-based approaches in chronic neurodegeneration: a glimpse into underlying mechanisms, current status, and prospects (2022 · Cellular & Molecular Biology Letters · 被引 91)